Prediction of progression-free survival and risk stratification in advanced lung adenocarcinoma patients receiving EGFR-TKI therapy
Objective We aimed to investigate the clinical characteristics and computed tomography (CT) findings associated with progression-free survival (PFS) in patients with stage IIIB–IV epidermal growth factor receptor ( EGFR )-mutant lung adenocarcinoma (LAD) receiving tyrosine kinase inhibitors (TKIs) and to develop a model for PFS prediction and risk stratification. Materials and methods This retrospective study enrolled patients with stage IIIB–IV EGFR -mutant LAD who received TKI therapy and underwent pretreatment contrast-enhanced thoracic CT between January 2015 and April 2024. The Kaplan–Meier method was used to calculate the median survival time. The log-rank test was used to compare the differences in the survival curves between groups. The clinicoradiological findings associated with PFS were evaluated with a multivariate Cox regression model. The performance of the Cox regression model was assessed using the time-dependent area under the curve (AUC) and Harrell’s concordance index ( C -index). Non-parametric bootstrapping with 1,000 resamples was performed as internal validation to evaluate the robustness and discriminative ability of the model. Results A total of 242 patients (102 men and 140 women) with a mean age of 61 ± 11 years were included. The median PFS was 13 months. Multivariate analysis revealed that higher neuron-specific enolase (NSE, ≥18 ng/ml) (HR = 1.455), larger tumor size (≥5cm) (HR = 1.573), and the presence of liver metastasis (HR = 1.514) were associated with increased progression risk. On the other hand, treatment with third-generation EGFR-TKI therapy (HR = 0.694) and the presence of the vessel convergence sign (HR = 0.708) were associated with a significantly decreased risk of progression. We further constructed a nomogram based on the above five independent risk factors for predicting PFS. The C -index for predicting PFS was 0.623, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.646, 0.676, and 0.699, respectively. The high-risk and low-risk groups were significantly different ( p < 0.001), with an HR of 1.931. The internally validated corrected global C -index was 0.610, and the AUCs for predicting the 6-, 12-, and 24-month PFS were 0.635, 0.671, and 0.695, respectively. Conclusion A nomogram based on baseline clinicoradiological factors serves as a useful tool for predicting PFS and stratifying risk in patients with advanced EGFR -mutated LAD after TKI therapy.
Authors
- Chunju Wen
- Wenjian Tang
- Zhen Wu
- Yuan Kang
- Zhiqiang Zhang
- Junyuan Zhong
- Jiawei Feng
- Haisheng Wu
- Yuping Zeng
Institutions
- Nanchang University (CN)
- Ganzhou People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fonc.2026.1941043
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00